DE68924354T2 - Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm). - Google Patents

Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm).

Info

Publication number
DE68924354T2
DE68924354T2 DE68924354T DE68924354T DE68924354T2 DE 68924354 T2 DE68924354 T2 DE 68924354T2 DE 68924354 T DE68924354 T DE 68924354T DE 68924354 T DE68924354 T DE 68924354T DE 68924354 T2 DE68924354 T2 DE 68924354T2
Authority
DE
Germany
Prior art keywords
iddm
insulin
compositions
diabetes mellitus
dependent diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE68924354T
Other languages
English (en)
Other versions
DE68924354D1 (de
Inventor
Mark Atkinson
Noel Maclaren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68924354(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Florida filed Critical University of Florida
Application granted granted Critical
Publication of DE68924354D1 publication Critical patent/DE68924354D1/de
Publication of DE68924354T2 publication Critical patent/DE68924354T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE68924354T 1988-12-13 1989-12-08 Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm). Revoked DE68924354T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28363388A 1988-12-13 1988-12-13
US42705189A 1989-10-25 1989-10-25
PCT/US1989/005570 WO1990007117A1 (en) 1988-12-13 1989-12-08 Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus

Publications (2)

Publication Number Publication Date
DE68924354D1 DE68924354D1 (de) 1995-10-26
DE68924354T2 true DE68924354T2 (de) 1996-02-22

Family

ID=26962160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924354T Revoked DE68924354T2 (de) 1988-12-13 1989-12-08 Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm).

Country Status (8)

Country Link
EP (1) EP0448635B1 (de)
KR (1) KR910700459A (de)
AU (1) AU4815890A (de)
CA (1) CA2005300C (de)
DE (1) DE68924354T2 (de)
DK (1) DK112391D0 (de)
ES (1) ES2077670T3 (de)
WO (1) WO1990007117A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
WO1992003733A1 (en) * 1990-08-17 1992-03-05 University Of Florida Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus
DE69133393T2 (de) 1990-09-07 2005-06-16 The Regents Of The University Of California, Oakland Verfahren zur diagnose und behandlung von diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
AU8864791A (en) * 1990-10-02 1992-04-28 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
CA2103159A1 (en) * 1991-05-15 1992-11-16 Ake Lernmark Cloning and expression of human islet glutamic acid decarboxylase autoantigen
US5407802A (en) * 1991-12-26 1995-04-18 Immulogic Pharmaceutical Corporation Method of accessing the risks of developing type I diabetes
JPH07508503A (ja) * 1992-02-27 1995-09-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・リランド・スタンフオード・ジユニア・ユニバーシテイ 自己免疫性糖尿病のための初期抗原（ｅａｒｌｙ　ａｎｔｉｇｅｎ）
CA2118015A1 (en) * 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
DE4237244A1 (de) * 1992-11-04 1994-05-05 Elias Entwicklungslabor Fuer I Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633251B2 (en) * 1988-02-03 1993-01-28 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Also Published As

Publication number Publication date
EP0448635B1 (de) 1995-09-20
DK112391A (da) 1991-06-12
EP0448635A1 (de) 1991-10-02
CA2005300A1 (en) 1990-06-13
DK112391D0 (da) 1991-06-12
KR910700459A (ko) 1991-03-15
ES2077670T3 (es) 1995-12-01
WO1990007117A1 (en) 1990-06-28
AU4815890A (en) 1990-07-10
DE68924354D1 (de) 1995-10-26
CA2005300C (en) 2000-02-15

Similar Documents

Publication Publication Date Title
DE68924354D1 (de) Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm).
DE69334246D1 (de) Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
AT387247B (de) Kombiniertes verfahren zur thermischen und chemischen behandlung von lignocellulosehaltiger biomasse und zur gewinnung von furfural
DE3782576T3 (de) Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung.
NO901141D0 (no) Additiv og fremgangsmaate for behandling av underjordiske formasjoner.
DE68910175T3 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE69003009D1 (de) Verfahren zur Behandlung von Fasermaterialien.
DE68927030D1 (de) Verfahren zur Konservierung ophthalmischer Lösungen und Zusammensetzungen dafür
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE3887934T2 (de) Verfahren zur elektronischen Behandlung eines belichteten photographischen Materials.
DK440288A (da) Anvendelse af eicosapentaensyre og/eller docosahexaensyre til fremstilling af midler til behandling af diabetes mellitus
DE3852969T2 (de) Farbphotographische Silberhalogenidmaterialien und Verfahren zur Behandlung.
NO901272D0 (no) Sammensetning og fremgangsmaate for fjerning av sulfider.
DE68903208T2 (de) Verfahren zur thermischen behandlung von laktoferrin.
KR900012933A (ko) 당뇨병 및 과혈당증 치료제로 유용한 화합물 및 이의 제조방법
DE68917817T2 (de) Verfahren zur Herstellung von vernetzten Polycarbonaten und Zusammensetzungen daraus.
DE69011758D1 (de) Verfahren zur Herstellung von N-substituierten Maleinimiden.
ATA118987A (de) Kominiertes verfahren zur termischen und chemischen behandlung von lignocellulosehaltiger biomasse und zur gewinnung von furfural
DE3761377D1 (de) Verfahren zur aufarbeitung von 2-merkaptobenzthiazol enthaltenden teeren.
DE69015677D1 (de) 3-(2-Oxo-1-pyrrolidinyl)-propylsilane und Verfahren zur Herstellung der Silanverbindungen.
DE69103294T2 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
DE68925387T2 (de) Verfahren zur Behandlung von Immunotest-Proben, die Schleim enthalten
DE68918351T2 (de) Verfahren zur Herstellung von N-substituiertem Monochlorosuccinimid.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation